Skip to content

Trial Summary

This is an open-label, randomized, Phase 3 study in patients with locally advanced unresectable or metastatic GIST (advanced GIST) of avapritinib (also known as BLU-285) versus regorafenib in patients previously treated with imatinib and 1 or 2 other TKIs

Acronym:

VOYAGER

ACTRN/NCT /ethics:

NCT03465722

Scientific title:

Study of Avapritinib (BLU-285) vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic GIST

Sponsor / Cooperative group:

Blueprint Medicines Corporation

Trial & Patient Characteristics

Cancer TypeStomach & Oesophageal
Trial TypeTreatment
PhasePhase III
Age Range18 years and older
SexBoth
Tumour Stream -
Cancer StageLocally Recurrent or Locally Advanced
Anticipated Start Date2021-03-26
Anticipated End Date2023-04-01

Participating Hospitals

HospitalFlinders Medical Centre
Clinical Trial CoordinatorAlex Scott-Hoy
Emailalex.scott-hoy@sa.gov.au
Phone08 8204 4830
Principal InvestigatorAmitesh Roy
Recruitment StatusRecruitment on Hold